PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

OIPE		Application Number		10/674,575
TRANSMITTAL	•	Filing Date		September 29, 2003
CE OCTA 1 2005 FORM		First Named Inventor		David W. Morris
7 2005		Art Unit		To Be Determined
(to be the for the prespondence after in	nitial filing)	Examiner Name		To Be Determined
otal Number of Pages in This Submissi	on	Attorney Docket Num	ber	CHIR0063-100 (PP23355.0001)
				_
	ENCL	OSURES (check all that a	oply)	
Fee Transmittal Form	☐ Drawing	g(s)		After Allowance Communication to TC
Fee Attached	Licensin	ng-related Papers		Appeal Communication to Board of Appeals and Interferences
Amendment / Reply	Petition			Appeal Communication to TC Appeal Notice, Brief, Reply Brief)
After Final		to Convert to a onal Application		Proprietary Information
Affidavits/declaration(s)	Power of Change	of Attorney, Revocation of Correspondence s including Table A	□s	Status Letter
	☐ Termina	al Disclaimer	$I_{\mathbf{M}}$	Other Enclosure(s)

	Aπidavits/declaration(s)	Address including Table A	Status Letter
	Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):
	Express Abandonment Request	Request for Refund CD, Number of CD(s)	1. Statement Under 37 CFR 3.73(b) (1p.) with copy of executed Assignment from the Inventors to Sagres Discovery, Inc. (1p.).
	☐ Information Disclosure Statement	☐ Landscape Table on CD	
	Certified Copy of Priority Document(s)	Remarks	
	Reply to Missing Parts/ Incomplete Application		
	Reply to Missing Parts under 37 CFR1.52 or 1.53		
	SIGI	NATURE OF APPLICANT, ATTORN	EY, OR AGENT
	Firm	Cezen O'Connor	
	Signature	The thell	
	Printed Name	Gwilym J.O. Attwell	
	Date		leg. 45,449 0.
,		CERTIFICATE OF TRANSMISSIO	N/MAILING

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

October 28 2005

Gwilym J.O. Attwell, Registration No. 45,449

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450 on the date shown below.

Signature

Typed or printed name

OCT 3,1 2005 & THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

POWER OF ATTORNEY WITH REVOCATION AND CHANGE OF CORRESPONDENCE ADDRESS

Thereby ap	ppoint:	·
prosecute t	Practitioners at Customer Number: 55255 as my/o the applications identified in the attached Table A, ted States Patent and Trademark Office connected	, and to transact all business
Address all	ll telephone calls and correspondence to:	

Lisa E. Alexander Sagres Discovery, Inc. c/o Chiron Corporation P.O. Box 8097 Emeryville, CA 94662-8097 Telephone: (510) 923-2585

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

Signature of Applicant or Assignee of Record

Respectfully submitted,
SAGRES DISCOVERY, INC.

Date: 24 August 2005

Name: Lisa E. Alexander

Title: Assistant Secretary



Table A

					40 a0
Docket No.	Serial No.	Inventor(s)	Examiner	Art Unit	Title
	Filing Date				
CHIR0021-100	10/035,832	David W. Morris et al.	n/a	1642	NOVEL COMPOSITIONS AND
PP23698.001	12/26/2001		5		METHODS FOR BREAST
					CANCER
CHIR0022-100	10/085,117	David W. Morris et al.	Sean E. Aeder	1642	NOVEL COMPOSITIONS AND
PP23697.001	2/27/2002				METHODS FOR CANCER
CHIR0023-100	10/087,192	David W. Morris et. al.	Alana M. Harris	1642	NOVEL COMPOSITIONS AND
PP23696.001	3/1/2002				METHODS FOR CANCER
CHIR0024-100	09/997,722	David W. Morris et al.	Sean E. Aeder	1642	NOVEL COMPOSITIONS AND
PP23794.001	11/30/2001				METHODS FOR CANCER
CHIR0025-100	10/105,612	David W. Morris et al.	Alana M. Harris	1642	NOVEL COMPOSITIONS AND
1172024.001	03/20/2002			_	METHODS IN CANCER
					ASSOCIATED WITH ALTERED EXPRESSION OF MCM3AP
CHIR0026-100	10/004,113		11 11 11	2/10	CITY OF WORLD OF THE PARTY OF T
PP23878.001	10/23/2001	Enc n. Engemard et al.	Alana M. narris	1047	METHODS FOR CANCER
CHIR0029-100	10/034,650	David W Morris et al	Sean F. Aeder	1642	NOVEL COMPOSITIONS AND
PP23793.001	12/20/2001				METHODS FOR CANCER
CHIR0030-100	10/105,871	David W. Morris et al.	n/a	1642	NOVEL COMPOSITIONS AND
PP23685.001	3/20/2002				METHODS IN CANCER
					ASSOCIATED WITH ALTERED
					EXPRESSION OF KCNJ9
CHIR0031-100 PP23695.001	10/105,637	David W. Morris et al.	Sean E. Aeder	1642	NOVEL COMPOSITIONS AND

	3/20/2002				METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF PRDM11
CHIR0035-100 PP23796.001	10/052,482 11/8/2001	David W. Morris et al.	Alana M. Harris	1642	NOVEL COMPOSITIONS AND METHODS FOR CANCER
CHIR0037-100 PP23693.001	10/105,613 3/20/2002	David W. Morris et al.	Sean E. Aeder	1642	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF TBX21
CHIR0038-100 PP23686.001	10/105,948 3/20/2002	David W. Morris et al.	Alana M. Harris	1642	NOVEL COMPOSITIONS AND METHODS IN CANCER ASSOCIATED WITH ALTERED EXPRESSION OF PRLR
CHIR0040-100 PP23650.002	10/020,508	David W. Morris et al.	n/a	n/a	METHODS AND COMPOSITIONS FOR INSERTION MUTATION SCANNING (IMS) OF GENOMES
CHIR0051-100 PP23371.002	10/394,948 3/21/2003	David W. Morris et al.	Quang Nguyen	1636	NOVEL COMPOSITIONS AND METHODS IN CANCER
CHIR0052-100 PP23370.001	10/322,281 12/17/2002	David W. Morris et al.	Alana M. Harris	1642	NOVEL COMPOSITIONS AND METHODS IN CANCER
CHIR0054-100 PP23369.001	10/331,053 12/26/2002	David W. Morris et al.	Teresa E. Strzelecka	1637	NOVEL COMPOSITIONS AND METHODS IN CANCER
CHIR0055-101 PP23350.0002	11/064,736 02/23/2005	David W. Morris et al.	n/a	n/a	NOVEL COMPOSITIONS AND METHODS IN CANCER

CHIR0056-100	10/330,773	David W Morris et al	e/u	n/a	NOVEL COMPOSITIONS AND
PP23367.001	12/27/2002				METHODS IN CANCER
CHIR0059-001	60/506,304	David W. Morris et al.	n/a	n/a	RHO ANTIBODY AND TAG
PP23360.001	9/25/2003				TO PURIFY CELL SURFACE PROTEINS
CHIR0060-001	60/507,682	David W. Morris et al.	n/a	n/a	NOVEL SPLICE VARIANTS OF
PP23359.001	9/30/2003				HUMAN
CHIR0062-100	10/692,382	David W. Morris et al.	n/a	n/a	NOVEL COMPOSITIONS AND
PP23356.002	10/22/2003				METHODS IN CANCER
CHIR0063-100	10/674,575	David W. Morris et al.	n/a	n/a	NOVEL COMPOSITIONS AND
PP23355.0001	9/29/2003				METHODS IN CANCER (AS
					AMENDED)
CHIR0065-100	10/883,878	David W. Morris et al.	n/a	n/a	NOVEL COMPOSITIONS AND
PP23349.001	7/1/2004				METHODS IN CANCER

OCT AND THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant, Sagres Discovery, Inc., states that it is:

the assignee of the entire right, title, and interest of the applications identified in Table A attached hereto.

The extent (by, percentage) of its ownership interest is 100% in the patent applications/patents identified in Table A.

a copy of the pertinent assignment from the inventor(s) of the patent applications/patents identified in Table A is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

SAGRES DISCOVERY, INC.

Date: HAugust 2005

Name: Lisa E. Alexander

Title: Assistant Secretary

ASSIGNMENT JOINT

THIS ASSIGNMENT, by David W. MORRIS and Marc S. MALANDRO (hereinafter referred to as the assignors), residing at 2841 Emerald Bay Drive, Davis, California 95616 and 1064 South Lake Drive, Gibsonia, Pennsylvania 15044, respectively, witnesseth:

WHEREAS, said assignors have invented certain new and useful improvements in NOVEL THERAPEUTIC TARGETS IN CANCER, set forth in an application for Letters Patent of the United States, bearing Serial No. 10/674,575 and filed on September 29, 2003; and

WHEREAS, Sagres Discovery, Inc., a corporation duly organized under and pursuant to the laws of Delaware and having its principal place of business at 2795 Second Street, Suite 400, Davis, California 95616 is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, said assignors have sold, assigned, transferred and set over, and by these presents do sell, assign, transfer and set over, unto said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignors, had this sale and assignment not been made.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, said assignors are the sole and lawful owners of the entire right, title and interest in and to said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that said assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignors hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that said assignors will, whenever counsel of said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

AND said assignors hereby request the Commissioner of Patents to issue said Letters Patent of the United States to said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said assignee, its successors, legal representatives and assigns.

Date

David W. MORRIS

Date

Marc S. MALANIORO